NASDAQ:PAVM
PAVmed Inc Stock News
$1.72
-0.0500 (-2.82%)
At Close: Apr 26, 2024
Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today
07:21pm, Wednesday, 10'th Apr 2024
PAVmed Inc. (PAVM) closed at $2.07 in the latest trading session, marking a -1.43% move from the prior day.
New Strong Buy Stocks for March 27th
08:21am, Wednesday, 27'th Mar 2024
RCL, PAVM, BANC, PRLB and IBP have been added to the Zacks Rank #1 (Strong Buy) List on March 27, 2023.
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
08:30am, Wednesday, 13'th Mar 2024
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 13, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical te
The 3 Most Undervalued Penny Stocks to Buy in December
03:00pm, Sunday, 17'th Dec 2023
We cannot end the year without adding a few penny stocks to our portfolio to take advantage of the opportunities coming up in the next cycle. Of course, we must rely on our investment thesis and our o
PAVmed Inc. (PAVM) Q3 2023 Earnings Call Transcript
07:00pm, Wednesday, 15'th Nov 2023
PAVmed Inc. (NASDAQ:PAVM ) Q3 2023 Earnings Call Transcript November 15, 2023 8:30 AM ET Company Participants Michael Parks - Vice President of Investor Relations Lishan Aklog - Chairman and Chief Exe
Here's Why PAVmed Inc. (PAVM) Is a Great 'Buy the Bottom' Stock Now
11:16am, Wednesday, 30'th Aug 2023
PAVmed Inc. (PAVM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wa
PAVmed Inc. (PAVM) Q2 2023 Earnings Call Transcript
05:18pm, Wednesday, 16'th Aug 2023
PAVmed Inc. (NASDAQ:PAVM ) Q2 2023 Earnings Conference Call August 16, 2023 8:30 AM ET Company Participants Michael Parks - Vice President of Investor Relations Lishan Aklog - Chairman and Chief Execu
3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024
08:00am, Wednesday, 24'th May 2023
Developing groundbreaking drugs and devices entails high costs, uncertain regulatory approval, and lucrative revenues. Those factors and more culminate to create a sector filled with dozens of biotech
PAVmed Inc. (PAVM) Upgraded to Strong Buy: Here's What You Should Know
01:45pm, Friday, 17'th Mar 2023
PAVmed Inc. (PAVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
PAVmed Inc. (PAVM) Q4 2022 Earnings Call Transcript
12:51pm, Wednesday, 15'th Mar 2023
PAVmed Inc. (NASDAQ:PAVM ) Q4 2022 Earnings Conference Call March 15, 2023 8:30 AM ET Company Participants Michael Parks – Vice President, Investor Relations Lishan Aklog – Chairman and CEO Dennis
PAVmed Inc. (PAVM) Q3 2022 Earnings Call Transcript
10:07pm, Tuesday, 15'th Nov 2022
PAVmed Inc. (NASDAQ:PAVM ) Q3 2022 Earnings Conference Call November 15, 2022 4:30 PM ET Company Participants Adrian Miller - VP, IR Lishan Aklog - Chairman and CEO Dennis McGrath - President and CFO
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2022
08:25am, Thursday, 03'rd Nov 2022
NEW YORK--(BUSINESS WIRE)---- $PAVM #1x1meetings--PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical device company today announced that the Company will host a business update
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
08:25am, Wednesday, 02'nd Nov 2022
NEW YORK--(BUSINESS WIRE)-- #CheckYourFoodTube--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PA
Best Penny Stocks To Buy? 5 Biotech Stocks For Your Watch List This Week
02:13pm, Monday, 24'th Oct 2022
Biotech penny stocks for your watch list this week. The post Best Penny Stocks To Buy?
Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday
06:33am, Monday, 22'nd Aug 2022 Benzinga
Gainers
GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday.
Aeglea BioTherapeutics, Inc. (NASDAQ: